Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David S Baldwin

Showing results (1-10 of 265) with videos related to

Pageof 27
Sort By:
Psychological Medicine|April 19, 2003
Recurrent brief depression--more investigations in clinical samples are now requiredDavid S Baldwin
Human Psychopharmacology|May 19, 2011
On reducing the duration of untreated illness in unipolar depressionDavid S Baldwin
Human Psychopharmacology|October 26, 2021
The first patient to receive olanzapine: A recollectionDavid S Baldwin
CNS Spectrums|September 30, 2006
Evidence-based guidelines for anxiety disorders: can they improve clinical outcomes?David S Baldwin
Addiction (Abingdon, England)|September 20, 2021
Clinical management of withdrawal from benzodiazepine anxiolytic and hypnotic medicationsDavid S Baldwin
International Clinical Psychopharmacology|April 24, 2020
A personal account of reducing and stopping antidepressant treatmentDavid S Baldwin
Expert Opinion on Drug Safety|September 1, 2004
Sexual dysfunction associated with antidepressant drugsDavid S Baldwin
Medicine (Abingdon, England : UK Ed.)|September 8, 2020
What is the role of a psychiatrist in the COVID-19 pandemic?David S Baldwin
International Journal of Psychiatry in Clinical Practice|June 13, 2014
Serotonin noradrenaline reuptake inhibitors: A new generation of treatment for anxiety disordersDavid S Baldwin
Human Psychopharmacology|October 12, 2012
Where is the room for improvement in the drug treatment of depression and anxiety?David S Baldwin
Pageof 27

Showing results (1-10 of 265) with videos related to

Sort By:
Pageof 27
Psychological Medicine|April 19, 2003
Recurrent brief depression--more investigations in clinical samples are now requiredDavid S Baldwin
Human Psychopharmacology|May 19, 2011
On reducing the duration of untreated illness in unipolar depressionDavid S Baldwin
Human Psychopharmacology|October 26, 2021
The first patient to receive olanzapine: A recollectionDavid S Baldwin
CNS Spectrums|September 30, 2006
Evidence-based guidelines for anxiety disorders: can they improve clinical outcomes?David S Baldwin
Addiction (Abingdon, England)|September 20, 2021
Clinical management of withdrawal from benzodiazepine anxiolytic and hypnotic medicationsDavid S Baldwin
International Clinical Psychopharmacology|April 24, 2020
A personal account of reducing and stopping antidepressant treatmentDavid S Baldwin
Expert Opinion on Drug Safety|September 1, 2004
Sexual dysfunction associated with antidepressant drugsDavid S Baldwin
Medicine (Abingdon, England : UK Ed.)|September 8, 2020
What is the role of a psychiatrist in the COVID-19 pandemic?David S Baldwin
International Journal of Psychiatry in Clinical Practice|June 13, 2014
Serotonin noradrenaline reuptake inhibitors: A new generation of treatment for anxiety disordersDavid S Baldwin
Human Psychopharmacology|October 12, 2012
Where is the room for improvement in the drug treatment of depression and anxiety?David S Baldwin
Pageof 27